featured
Ex Vivo Venetoclax Sensitivity Testing Predicts Treatment Response in Patients With AML
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
Haematologica
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Ex vivo venetoclax sensitivity testing predicts treatment response in acute myeloid leukemia
Haematologica 2022 Dec 15;[EPub Ahead of Print], H Kuusanmäki, S Kytölä, I Vänttinen, T Ruokoranta, A Ranta, J Huuhtanen, M Suvela, A Parsons, A Holopainen, A Partanen, MEL Kuusisto, S Koskela, R Räty, M Itälä-Remes, I Västrik, O Dufva, S Siitonen, K Porkka, K Wennerberg, CA Heckman, P Ettala, M Pyörälä, J Rimpiläinen, T Siitonen, M KontroFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.